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TheAssociationBetweenPhosphodiesterase-5 Inhibitors
and Colorectal Cancer in a National Cohort of Patients
S. Scott Sutton, PharmD1,2, Joseph Magagnoli, MS1,2, Tammy H. Cummings, PhD1,2 and James W. Hardin, PhD2,3
INTRODUCTION: Toexamine theassociationbetweenphosphodiesterase-5 (PDE-5) inhibitor useand incidenceof colorectal
cancer among patients with erectile dysfunction treated in the Veterans Affairs (VA) Healthcare System.
METHODS: A retrospective cohort study using the Veterans Affairs Informatics and Computing Infrastructure was
conducted, with data spanning January 2001–December 2016. Patients were followed up from index
until (i) the first diagnosis of colorectal cancer, (ii) death, or (iii) the end of study period. Statistical
analyses evaluated demographics and baseline characteristics between cohorts (PDE-5 exposed or not)
and the effect of additional dosages of each specific PDE-5 inhibitor using adjusted multivariate Cox
proportional hazards models.
RESULTS: A total of 221,538 patientsmet the study inclusion criteria, 192,691 patients in the PDE-5 cohort and
29,227patients in the never usePDE-5 cohort. ThemultivariateCox proportional hazardsmodel results
revealed that the those who had any exposure to a PDE-5 inhibitor have an 18% lower hazard of
colorectal cancer (adjusted hazard ratio [HR]50.816, 95%confidence interval [CI]50.754–0.882).
For each additional 100-mg dosage of sildenafil and 10-mg dosage of tadalafil, the hazard of colorectal
cancer is reduced by 2.4% (adjustedHR50.976, 95%CI50.973–0.979) and 1.7% (adjustedHR5
0.983, 95% CI 5 0.972–0.996), respectively.
DISCUSSION: PDE-5 inhibitor usage in patients with erectile dysfunction is associated with a lower hazard of
colorectal cancer compared with patients not exposed to PDE-5 inhibitors.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A281
Clinical and Translational Gastroenterology 2020;11:e00173. https://doi.org/10.14309/ctg.0000000000000173
INTRODUCTION
Colorectal cancer is one of the most common and deadly cancers
(1). Research suggests that phosphodiesterases (PDEs) are involved
in the development and progression of colorectal cancer (2,3). One
type of PDE isozyme is the PDE-5, which is specific to cyclic
guanosine monophosphate. Currently, PDE-5 inhibitors are ap-
proved by the US Food and Drug Administration to treat erectile
dysfunction (t) (4). However, PDE-5 inhibitors may be a viable
chemopreventive agent. Evidence suggests that targeting cyclic
guanosine monophosphate with PDE-5 inhibitors can reduce the
incidenceof intestinal cancer via altering epithelial homeostasis (5).
Furthermore, recent preclinical studies including in vivo, in vitro,
andmouse studies suggest that PDE-5 inhibitor usemay reduce the
risk of colorectal cancer (4,6–11).
Given the preclinical evidence, the purpose of this study is to
evaluate the association between PDE-5 inhibitor use and in-
cident colorectal cancer diagnosis in a large national cohort.
METHODS
Data
This retrospective cohort study was conducted using data from the
Department of Veterans Affairs. The Veterans Affairs Informatics
and Computing Infrastructure was used to obtain individual-level
information on demographics, administrative claims, and phar-
macy dispensation. The completeness, utility, accuracy, validity,
and access methods are described on the Veterans Affairs (VA)
website, http://www.virec.research.va.gov. The study was con-
ducted in compliance with the Department of Veterans Affairs
requirements and received the Institutional Review Board and
Research andDevelopment approval. The study used the inpatient
and outpatient data (coded with International Classification of
Diseases [ICD] revision9-CM, revision10-CM,CurrentProcedure
Terminology) andpharmacy, laboratory, and vital sign data, which
include height, weight, and blood pressure, over the time period
January 2000–December 2018.
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Cohort selection
The cohort for this study includes all male veterans aged 18 years
and older with a diagnosis of ED. ICD revision 9 and 10 codes
including 302.72, 607.84, and N52.9x were used to code ED be-
tween January 2001 and December 31, 2016. The study index date
for patients was defined as the first diagnosis of ED. The study
period, for each patient, was defined as the time between index and
study endpoint. The baseline period was defined as 1 year before
study index.
We used several exclusionary criteria. Patients were included if they
had at least 1 year between theirVAenrollment date and study index
date. To account for latency bias, patients were excluded if they had
a diagnosis of colorectal cancer or died up until 1 year after index
(12,13). Patients were excluded if they did not have any values of
estimated glomerular filtration rate (eGFR), systolic, diastolic blood
pressure, body mass index (BMI), or serum cholesterol during the
baseline period to ensure proper medical surveillance. Furthermore,
patients who had a PDE-5 inhibitor prescription during baseline
were excluded. Patients with prescriptions for nitroglycerin were
excluded from the study because PDE-5 inhibitors are contra-
indicated for patients on nitroglycerin. To ensure whether patients
had the opportunity to be diagnosed with colorectal cancer, all
patients were required to have at least 1 colonoscopy during the
study period. Colonoscopies were extracted from the outpatient
claims using Current Procedure Terminology codes: 45378-45398.
Patients with pulmonary arterial hypertension were excluded using
the ICD-9/10 diagnosis codes (416.0, 416.8, 416.9, I27.2x, I27.81,
I27.89, and I27.9) and any patient with a PDE-5 inhibitor pre-
scription for greater than 1 pill per day. Pills per day were calculated
using the quantity supplied divided by the days supplied. Patients
were followed up from index until
1. the first diagnosis of colorectal cancer
2. death
3. the end of study period December 31, 2018.
Outcome
The outcome for this study was the development of colorectal
cancer, defined as the first diagnosis of the following ICD-9 and
10 codes: 153.x, 154.0, 154.1, C18.3, C18.4, C18.5, C18.6, C18.7,
C18.8, C18.9, C19, and C20 (12).
Study variables
The primary predictor of interest is the use of PDE-5 inhibitors.
PDE-5 inhibitors comprised sildenafil, tadalafil, vardenafil, and
avanafil.Wequantified the exposure to PDE-5 inhibitors in 2ways.
First, patients who had at least 1 prescription for a PDE-5 inhibitor
were classified as PDE-5 inhibitor users and those without a pre-
scription for a PDE-5 were classified as never users. Second, we
used the cumulative milligrams (mg) prescribed for each PDE-5
inhibitor. Dosages were extracted from the drug name and sum-
med over the study period.
In addition toPDE-5 use,we also included covariates to account
for baseline demographic and health differences. Demographic
factors included age, race, and index year. Baseline health con-
ditions included theCharlson comorbidity index, diabetes, tobacco
usage, BMI, systolic and diastolic blood pressure, eGFR (chronic
kidney disease-epi formula), total serum cholesterol, and family
history of gastrointestinal malignant neoplasm and inflammatory
bowel disease (IBD). Baseline laboratory values including eGFR
and serum cholesterol were extracted using logical observation
identifiers names and codes (see Appendix, Supplementary Digital
Content 1, http://links.lww.com/CTG/A281). Diagnoses of the
family history of gastrointestinal malignant neoplasm, diabetes,
tobacco usage were coded based on the ICD-9 and ICD-10 di-
agnoses codes (see Appendix, Supplementary Digital Content 1,
http://links.lww.com/CTG/A281).
Statistical analysis
The statistical analysis occurred in 2 steps. First, we compared the
baseline characteristics between those exposed to PDE5 inhibitors
and the never exposed patients. Second, we displayed the
Kaplan–Meier survival curves for the PDE-5 exposed and un-
exposed cohorts to display the unadjusted survival curves.Weused
the multivariate Cox proportional hazards models to estimate the
hazard of developing colorectal cancer.Our initialmodel compares
the hazard of those exposed to any PDE-5 inhibitor with that of
those never exposed. Next, we estimated the effect of additional
dosages of each specific PDE-5 inhibitor; however, avanafil was
excluded from drug-specific models because of low sample counts.
A subanalysis was conducted on patients who had monotherapy
(i.e., exposed to only 1 PDE-5 inhibitor) compared with those who
were never exposed to sildenafil or vardenafil (due to sample sizes).
In addition to estimating the hazard ratios per additional dosages,
we also estimated the hazard ratios for the total number of PDE-5
prescriptions. Prescription counts were categorized into 5 groups
(1–4, 5–10, 11–15, 16–20, and 211).
RESULTS
In this study, we found 1.7 million male veterans with a diagnosis
for ED over the years 2001–2016. We excluded 406,385 patients
who had a PDE-5 inhibitor prescribed before study index. In total,
295,359 patients were excluded because they did not have at least 1
year between VA enrollment and study index; 2,081 patients who
had colorectal cancer up until 1 year after index were excluded;
13,392 patients were excluded because they died within 1 year after
index; 55,549 patients were excluded because they were missing
baseline laboratory test results; 155,668 patients with a prescription
for nitroglycerine were removed from the study; 573,987 patients
were excluded because they did not have a colonoscopy during the
study period; and 8,353 patients were excluded for pulmonary
Figure 1. Study attrition. BMI, body mass index; ED, erectile dysfunction;
eGFR, estimated glomerular filtration rate; PDE, phosphodiesterase; VA,
Veterans Affairs.
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arterial hypertension. After all exclusionary criteria, 221,538
patients remained in the study cohort (Figure 1).
Table 1 displays the demographic and baseline clinical charac-
teristics for patients who never used a PDE-5 inhibitor (n5 29,227)
and those who had at least 1 PDE-5 inhibitor prescription
(n5 192,691). On average, those who never used a PDE-5 inhibitor
are older (60.51 vs 57.13 years, respectively), have a higher Charlson
comorbidity index (1.17 vs 0.75, respectively), have a lower eGFR
(78.89 vs 83.48), have lower total serum cholesterol (181.91 vs
186.46), andhave ahigher prevalence of diabetes (27.24%vs 20.47%).
Patients who took a PDE-5 inhibitor have a higher prevalence of
statin usage (63.95% vs 36.27%) and are more likely to be smokers
(19.04% vs 16.42%). The breakdown of PDE-5 use by drug is shown
in Table 2. Of the PDE-5 inhibitor users, 86% has at least 1
Table 1. Demographic and baseline clinical characteristics
Variable
PDE-5 inhibitor use
P value Std diffNever (N 5 29,227) Yes (N 5 192,691)
Age 60.51 (9.567) 57.13 (8.524) ,0.001 0.3739
Race
Asian 115 (0.393%) 916 (0.476%) ,0.001 0.2886
Black 4,802 (16.402%) 54,332 (28.26%)
Latino/Hispanic 98 (0.335%) 733 (0.381%)
Other/unknown 2,234 (7.631%) 11,171 (5.81%)
White 22,028 (75.24%) 125,109 (65.072%)
Charlson comorbidity index 1.17 (1.564) 0.75 (1.244) ,0.001 0.2930
BMI
Normal 4,370 (14.926%) 29,219 (15.198%) ,0.001 0.0482
Obese 13,856 (47.327%) 86,250 (44.861%)
Overweight 10,898 (37.224%) 75,778 (39.414%)
Underweight 153 (0.523%) 1,014 (0.527%)
eGFR 78.89 (19.46) 83.48 (17.979) ,0.001 0.2455
Total serum cholesterol (mg/dL) 181.91 (40.724) 186.46 (40.25) ,0.001 0.1125
Systolic blood pressure 133.29 (17.282) 132.2 (16.074) ,0.001 0.0652
Diastolic blood pressure 77.15 (10.971) 78.71 (10.408) ,0.001 0.1463
Family history of malignant GI neoplasm 245 (0.837%) 1,793 (0.933%) 0.117 0.0109
Diabetes 7,976 (27.243%) 39,360 (20.472%) ,0.001 0.1577
Smoking 4,807 (16.419%) 36,606 (19.04%) ,0.001 0.0682
IBD 290 (0.991%) 1,544 (0.803%) 0.001 0.0212
Statin use 10,618 (36.267%) 122,965 (63.957%) ,0.001 0.5766
NSAID use 20,311 (69.5%) 146,573 (76.1%) ,0.001 0.1487
Index year 2,006.88 (4.282) 2,006.84 (3.913) 0.132 0.0091
Days in study 3,502.84 (1,560.903) 3,828.63 (1,450.143) ,0.001 0.2163
Format: categorical variables N (%); continuous variables mean (SD).
BMI, body mass index; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; IBD, inflammatory bowel disease; NSAID, nonsteroidal anti-inflammatory drug;
PDE, phosphodiesterase.
Table 2. PDE-5 inhibitor usage
PDE-5 inhibitor N (% all PDE-5) Monotherapy N (% within drug) Average cumulative mg dose (SD)
Sildenafil 166,208 (86.449%) 50,758 (30.50%) 1,884 (2,514.19)
Tadalafil 7,896 (4.107%) 202 (2.60%) 135.34 (227.69)
Vardenafil 140,067 (72.853%) 25,514 (18.20%) 253.73 (306.12)
Avanafil 117 (0.061%) 1 (0.95%) 433.33 (517.28)
PDE, phosphodiesterase.
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prescription for sildenafil, 72% had a prescription for vardenafil, 4%
for tadalafil, and 0.9% for avanafil. Among those with a sildenafil
prescription, 30% had no other PDE-5 inhibitors. Among those with
avardenafil prescription, 18%hadnootherPDE-5 inhibitors.Among
those with tadalafil exposure, 2.6% were exposed only to tadalafil.
Among those exposed to avanafil, only 1 patient was exposed only to
avanafil. Figure 2 presents the unadjusted Kaplan–Meier survival
curves for those exposed and unexposed to a PDE-5 inhibitor. The
Kaplan–Meier curves showed a lower risk of colorectal cancer
throughout the study time. In Table 3, we present the results of the
Cox proportional hazard model, examining the association between
any PDE-5 inhibitor use and colorectal cancer. Those who had any
exposure to aPDE-5 inhibitor have an18% lowerhazard of colorectal
cancer (hazard ratio [HR]5 0.816, 95% confidence interval [CI]5
0.754–0.882). Black patients had a higher hazard of colorectal cancer
compared with white patients (HR5 1.168, 95%CI5 1.089–1.252).
Other risk factors for colorectal cancer included age (HR 5 1.056,
95%CI5 1.052–1.060), Charlson comorbidity (HR5 1.067, 95%CI
5 1.042–1.093), total serum cholesterol (HR 5 1.005, 95% CI 5
1.003–1.007), diastolic blood pressure (HR 5 1.002, 95% CI 5
1.001–1.003), diabetes (HR 5 1.196, 95% CI 5 1.105–1.295),
smoking (HR 5 1.164, 95% CI 5 1.075–1.259), and IBD (HR 5
1.411, 95% CI5 1.061–1.876). Statins, consistent with Poynter et al.
(14), are associated with a decrease in the hazard of colorectal cancer
(HR5 0.613, 95% CI5 0.576–0.652).
The results from the association between drug dosage and co-
lorectal cancer are shown in Table 4. For each additional 100-mg
dosage of sildenafil, the hazard of colorectal cancer is reduced by
2.4% (HR5 0.976, 95%CI5 0.973–0.979). For each additional 10-
mg dose of tadalafil, the hazard of colorectal cancer is reduced by
1.7% (HR5 0.983, 95%CI5 0.972–0.996).Wefindno statistically
significant association for each additional 10-mg vardenafil dose
(HR5 1.000, 95% CI5 0.999–1.002). Other results are similar to
those of the cox proportional hazards model examining the asso-
ciation between any PDE-5 inhibitor use and colorectal cancer.
Table 5 displays the subanalysis conductedon thosewith noPDE-5
inhibitor exposure and those with sildenafil-only treatment, and
secondarily those with no PDE-5 inhibitor exposure and
vardenafil-only treatment. We find that each additional 100 mg of
sildenafil, the hazard of colorectal cancer is reduced by 1% (HR5
0.99, 95% CI 5 0.984–0.995). For each additional 10 mg of
vardenafil, there is an associated 0.7% higher hazard of colorectal
cancer (HR5 1.007, 95% CI5 1.002–1.011). Table 6 displays the
results of the Cox model estimating PDE-5 exposure by pre-
scription counts. We found that patients with less than or equal to
10 prescriptions are not statistically significantly different in the
risk of colorectal cancer compared with the unexposed (1–4 HR5
1.024, 95% CI 5 0.936–1.119; 5–10 HR 5 0.969, 95% CI 5
0.877–1.071). Patients with greater than 10 prescriptions for
a PDE-5 have a statistically significantly lower risk of colorectal
cancer (11–15 HR5 0.878, 95% CI5 0.774–0.995; 16–20 HR5
0.841, 95% CI 5 0.73–0.968; 211 HR 5 0.536, 95% CI 5
0.486–0.59). Furthermore, the estimates suggest that the risk of
colorectal cancer decreases for additional prescriptions of a PDE-5,
ultimately resulting in a 46% reduction in risk for those with 21 or
more prescriptions (211HR5 0.536, 95% CI5 0.486–0.59).
DISCUSSION
In this study, among patients receiving care in the VA system
with ED, we found that those who had any exposure to a PDE-5
Figure 2. Kaplan–Meier survival curves. PDE, phosphodiesterase.
Table 3. Multivariate Cox proportional hazards model estimating
the hazard of developing colorectal cancer
Variable HR (95% CI)
PDE-5 inhibitor use (referent5 never used)
Yes 0.828 (0.766–0.895)
Age 1.051 (1.047–1.055)
Race (referent 5White)
Asian 1.188 (0.765–1.845)
Black 1.283 (1.196–1.376)
Latino/Hispanic 0.942 (0.567–1.565)
Other/unknown 0.831 (0.729–0.947)
Charlson comorbidity index 1.081 (1.056–1.106)
BMI (referent 5 underweight)
Normal 1.24 (0.795–1.934)
Obese 1.277 (0.821–1.987)
Overweight 1.151 (0.74–1.789)
eGFR 1.001 (1–1.003)
Total serum cholesterol (mg/dL) 1.006 (1.003–1.008)
Systolic blood pressure 0.997 (0.993–1)
Diastolic blood pressure 1.002 (1.001–1.003)
Family history of malignant GI neoplasm 1.091 (0.802–1.484)
Diabetes 1.23 (1.136–1.331)
Smoking 1.211 (1.119–1.31)
IBD 1.32 (0.993–1.755)
Statins 0.632 (0.594–0.673)
Index year 0.938 (0.929–0.947)
NSAID use 0.449 (0.421–0.479)
BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular
filtration rate; GI, gastrointestinal; HR, hazard ratio; IBD, inflammatory bowel
disease; NSAID, nonsteroidal anti-inflammatory drug; PDE,
phosphodiesterase.
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inhibitor had a lower hazard of colorectal cancer. Furthermore,
we estimated the effect of additional dosages of each specific
PDE-5 inhibitor (excluding avanafil). We found for each addi-
tional 100-mg dosage of sildenafil and each additional 10-mg
dose of tadalafil, the hazard of colorectal cancer is reduced. In
the subanalysis, patients who had monotherapy with sildenafil
only had a decreased hazard of colorectal cancer for each ad-
ditional 100 mg of treatment. However, for each additional 10
mg of vardenafil, there is a higher hazard of colorectal cancer for
those on vardenafil only.
More in vivo studies have demonstrated the effectiveness of
PDE-5 inhibitors effect on the colon compared with in vitro
studies. Some in vivo studies showed that the sildenafil sup-
pressed the polyp multiplicity in the colon, even by 50% by
administering varying dosages of the inhibitor (6,7,10).
Growth inhibition of colon tumor cells occurred with the use of
PDE-5 inhibitors in vitro (and in vivo) while enhancing anti-
cancer and other drugs (8,11). Mei et al. (4) demonstrated the
effect of sildenafil on proliferation and apoptosis in vitro and in
vivo by implanting nude mice with SW480 or HCT116 human
cancer cells by administering sildenafil orally. Similar results
were shown in vitro and in vivo with sildenafil and tadalafil
inhibiting tumor growth in immune-competent mice by
50%–70% (9).
Although there is a lack of observational studies evaluating
the association of the use of PDE-5 inhibitors and colorectal
cancer, some results from our study is consistent with other
Table 4. Multivariate Cox proportional hazards model estimating
the hazard of colorectal cancer by dose
Variable HR (95% CI)
Sildenafil per additional 100 mg 0.977 (0.974–0.979)
Tadalafil per additional 10 mg 0.985 (0.973–0.997)
Vardenafil per additional 10 mg 1.001 (0.999–1.002)
Age 1.044 (1.04–1.048)
Race (referent 5 White)
Asian 1.245 (0.802–1.934)
Black 1.438 (1.341–1.543)
Latino/Hispanic 1.026 (0.618–1.705)
Other/unknown 0.839 (0.736–0.956)
Charlson comorbidity index 1.071 (1.046–1.096)
BMI (referent5 underweight)
Normal 1.269 (0.814–1.979)
Obese 1.279 (0.822–1.99)
Overweight 1.18 (0.758–1.835)
eGFR 1.002 (1–1.003)
Total serum cholesterol (mg/dL) 1.005 (1.003–1.007)
Systolic blood pressure 0.997 (0.994–1.001)
Diastolic blood pressure 1.002 (1.001–1.002)
Family history of malignant
GI neoplasm
1.088 (0.8–1.48)
Diabetes 1.197 (1.106–1.295)
Smoking 1.205 (1.114–1.304)
IBD 1.313 (0.987–1.746)
Statins 0.688 (0.647–0.732)
Index year 0.928 (0.919–0.938)
NSAID use 0.468 (0.439–0.499)
BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular
filtration rate; GI, gastrointestinal; HR, hazard ratio; IBD, inflammatory bowel
disease; NSAID, nonsteroidal anti-inflammatory drug.
Table 5. Multivariate Cox proportional hazards model estimating
the hazard of colorectal cancer for those on monotherapy
Variable HR (95% CI) HR (95% CI)
PDE-5 inhibitor use
(referent 5 never used)
Sildenafil monotherapy
per additional 100 mg
0.991 (0.986–0.997)
Vardenafil
monotherapy per
additional 10 mg
1.007 (1.003–1.011)
Age 1.047 (1.041–1.053) 1.041 (1.034–1.048)
Race (referent5 White)
Asian 1.55 (0.855–2.808) 1.006 (0.417–2.424)
Black 1.415 (1.265–1.583) 1.416 (1.249–1.606)
Latino/Hispanic 1.064 (0.506–2.237) 1.762 (0.878–3.536)
Other/unknown 0.858 (0.718–1.026) 0.856 (0.701–1.046)
Charlson comorbidity
index
1.089 (1.055–1.124) 1.062 (1.024–1.101)
BMI (referent 5
underweight)
Normal 1.146 (0.611–2.151) 1.26 (0.595–2.672)
Obese 1.184 (0.633–2.214) 1.314 (0.622–2.773)
Overweight 1.082 (0.579–2.023) 1.204 (0.571–2.54)
eGFR 1.002 (1–1.005) 1.002 (0.999–1.004)
Total serum cholesterol
(mg/dL)
1.003 (1–1.006) 1.004 (1.001–1.008)
Systolic blood pressure 1.001 (0.996–1.007) 1.001 (0.995–1.007)
Diastolic blood
pressure
1.002 (1.001–1.003) 1.002 (1.001–1.003)
Family history of
malignant GI neoplasm
1.006 (0.615–1.645) 1.089 (0.655–1.811)
Diabetes 1.187 (1.057–1.331) 1.142 (1.006–1.296)
Smoking 1.335 (1.185–1.503) 1.246 (1.093–1.421)
IBD 0.822 (0.502–1.345) 1.027 (0.617–1.708)
Statins 0.756 (0.691–0.828) 0.831 (0.75–0.922)
Index year 0.892 (0.881–0.904) 0.927 (0.912–0.943)
NSAID use 0.446 (0.406–0.49) 0.451 (0.407–0.5)
BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular
filtration rate; GI, gastrointestinal; HR, hazard ratio; IBD, inflammatory bowel
disease; NSAID, nonsteroidal anti-inflammatory drug; PDE,
phosphodiesterase.
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studies. A UK-matched cohort study found a decreased risk for
colorectal cancer for those who were PDE-5 inhibitor users
(HR5 0.91, 95% CI5 0.85–0.98, P5 0.01); however, they did
not limit their analyses to men with ED (15). In a Swedish study
of men diagnosed with benign colorectal neoplasm had a re-
duced risk of colorectal cancer (HR5 0.65, 95%CI5 0.49–0.85)
while using PDE-5 and an increased cumulative dosage of
PDE-5 (16). PDE-5 is effective enough to selectively stimulate
apoptosis of colon tumor cells while having minimal effects on
normal colon cells (17,18).
Some demographic and risk factors that we adjusted for in
our models are included in other literature concerning co-
lorectal cancer. Differences in colorectal cancer are seen in
racial disparities, as blacks are associated with having a higher
incidence (19,20). Clinical studies of IBD report that patients
have a higher risk of colorectal cancer as well (7,21). Statin users
had a decreased risk of colorectal cancer compared with non-
statin users (13). Patients with diabetes, consistent with
Overbeek et al. (22), have an increased risk of developing co-
lorectal cancer; however, the study did not account for smoking
status nor BMI in estimatingmodels as we did. UnlikeMamtani
et al., we found an increased total serum cholesterol to be as-
sociated with an increased hazard of colorectal cancer similar to
another study (13,23). A meta-analysis demonstrated that
cigarette smoking is associated with an increased incidence and
mortality of colorectal cancer among a sample of 106 stud-
ies (24).
To our knowledge, this study is the first population-based
study to examine the function of PDE-5 inhibitors along with
the risk of colorectal cancer among patients with ED. Our study
is unique because it (i) evaluated a national cohort of patients
with ED, (ii) evaluated patients who were prescribed PDE-5
inhibitors (sildenafil, tadalafil, vardenafil, and avanafil), and (iii)
evaluated PDE-5 usage 2 ways (binary and dosage). However,
like many observational studies, there are some factors that may
have influenced the outcomes which were not accounted for
within this study. First, the population is US male veterans with
ED; therefore, our findings may not be generalizable to other
patients. We were unable to exclude unmeasured potential
confounding factors that may have influenced our outcomes
because patients were not randomized to different treatments.
Although we attempted to control for select variables by using
adjusted models, residual confounding may remain. Finally,
medication usage was measured from filled prescriptions, and
we cannot confirm that patients adhered to their prescriptions;
however, studies have advocated that pharmacy refill rates and
prescription claims data are a good depiction for actual medi-
cation adherence (25). Despite the limitations of this study, we
believe that the data are robust for our large sample within the
US Veteran population and will add to the current literature on
the incidence of colorectal cancer and the use of PDE-5
inhibitors.
Our study evaluated the association of colorectal cancer and
PDE-5 inhibitors among a national cohort of patients with ED
within the VA system. Those who were prescribed PDE-5
inhibitors had a reduced hazard of colorectal cancer compared
with those who were never prescribed PDE-5 inhibitors. For
each additional 100-mg dosage of sildenafil and each addi-
tional 10-mg dosage of tadalafil, the hazard of colorectal cancer
was reduced as well. According to our research, clinicians
should monitor and understand the risks and benefits of PDE-
5 inhibitors with the occurrence of colorectal cancer among
patients with ED. Further research is needed to confirm the
observed association.
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Table 6. Multivariate Cox proportional hazards model estimating
the hazard of colorectal by the number of refills
Variable HR (95% CI)
PDE-5 exposure refill count
(referent5 never used)
1–4 1.024 (0.936–1.119)
5–10 0.969 (0.877–1.071)
11–15 0.878 (0.774–0.995)
16–20 0.841 (0.73–0.968)
211 0.536 (0.486–0.59)
Age 1.046 (1.041–1.05)
Race (referent 5 White)
Asian 1.228 (0.791–1.907)
Black 1.397 (1.302–1.5)
Latino/Hispanic 0.989 (0.595–1.643)
Other/unknown 0.84 (0.737–0.957)
Charlson comorbidity index 1.073 (1.048–1.099)
BMI (referent 5 underweight)
Normal 1.251 (0.802–1.951)
Obese 1.263 (0.812–1.965)
Overweight 1.158 (0.745–1.802)
eGFR 1.001 (1–1.003)
Total serum cholesterol (mg/dL) 1.005 (1.003–1.007)
Systolic blood pressure 0.997 (0.994–1.001)
Diastolic blood pressure 1.002 (1.001–1.002)
Family history of malignant
GI neoplasm
1.09 (0.801–1.483)
Diabetes 1.21 (1.118–1.31)
Smoking 1.209 (1.117–1.308)
IBD 1.312 (0.987–1.745)
Statins 0.676 (0.635–0.72)
Index year 0.931 (0.922–0.941)
NSAID use 0.464 (0.436–0.495)
BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular
filtration rate; GI, gastrointestinal; HR, hazard ratio; IBD, inflammatory bowel
disease; NSAID, nonsteroidal anti-inflammatory drug; PDE,
phosphodiesterase.
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Study Highlights
WHAT IS KNOWN
3 Recent preclinical studies including in vivo, in vitro, and
mouse studies suggest that PDE-5 inhibitor use may reduce
the risk of colorectal cancer.
WHAT IS NEW HERE
3 We use a large national cohort of patients being treated in the
VA and show that PDE-5 inhibitor use is associated with
a lower risk of colorectal cancer.
TRANSLATIONAL IMPACT
3 PDE-5 inhibitors show evidence to support a new drug
development or additional indications for PDE-5 inhibitors.
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